CD8A and non-small cell lung carcinoma: As so far, many kinds of immune cells in peripheral were found to be promising to predict immunotherapy efficacy in advanced NSCLC without driver gene mutation, such as the ratio of neutrophil-to-lymphocyte (NLR), TCR clonality and diversity of T cells, memory T cells, and the amount and function of CD8+T cells or immunosuppressive cells eg. regular T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) [19].